Literature DB >> 8793035

The participation of interleukin-6, a stress-inducible cytokine, in the pathogenesis of Alzheimer's disease.

M Hüll1, S Strauss, M Berger, B Volk, J Bauer.   

Abstract

A loss of synapses in the cortices of demented persons appears to be the primary correlate of Alzheimer's disease (AD). However, it is still unclear how synaptic pathology is connected to other pathological findings such as neurofibrillary and neuritic degeneration or inflammatory markers in AD. Interleukin-6 (IL-6) immunoreactivity has previously been detected in plaques in the brains of AD patients. In addition, elevated IL-6 concentrations have been measured biochemically in the brains of AD patients. Since transgenic mice bearing additional copies of the IL-6 gene under the control of a brain-specific promoter develop a marked cortical pathology including severe alterations of the dendritic arborization of cortical neurons, an IL-6 related inflammatory event could well be connected to the synaptic pathology in AD. In this study, we investigated whether IL-6 immunoreactivity in plaques could already be found prior to the onset of neuritic changes, or whether the presence of this cytokine is restricted to the later stages of plaque formation. While diffuse plaques represent an early stage of plaque formation, primitive and classic plaques (displaying neuritic pathology) are thought to reflect later stages of plaque pathology. Using a silver-staining method, we classified plaque stages in serial sections of paraffin-embedded cortices of clinically diagnosed and histopathologically confirmed AD patients and of control persons with no clinical history of dementia. Adjacent sections were stained with an antibody directed against IL-6. IL-6 was detectable in a significant proportion of plaques, but only in the brains of demented patients. In the AD cases, IL-6 was found in diffuse plaques in a significantly higher ratio as would have been expected from a random distribution of IL-6 among all plaque types. This observation suggests that IL-6 expression may precede neuritic changes and that in AD an immunological mechanism may be involved both in the transformation from diffuse to primitive plaques and in the development of dementia. The reasons for the increased expression of IL-6 in the brains of AD patients are still unknown. Basal IL-6 levels were found to be slightly elevated along normal aging. Based on several studies indicating that IL-6 expression is inducible also by psychological stress, one could speculate whether long-lasting stressful experiences may contribute to the pathological process underlying Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8793035     DOI: 10.1016/0166-4328(95)00213-8

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  25 in total

1.  The effect of stress on the onset and progression of Creutzfeldt-Jakob disease: results of a German pilot case-control study.

Authors:  C Laske; O Gefeller; A Pfahlberg; I Zerr; A Schröter; S Poser
Journal:  Eur J Epidemiol       Date:  1999-08       Impact factor: 8.082

Review 2.  The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment.

Authors:  G Stennis Watson; Suzanne Craft
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 3.  Diabetes mellitus and Alzheimer's disease: shared pathology and treatment?

Authors:  Kawser Akter; Emily A Lanza; Stephen A Martin; Natalie Myronyuk; Melanie Rua; Robert B Raffa
Journal:  Br J Clin Pharmacol       Date:  2011-03       Impact factor: 4.335

Review 4.  Physiological and pathological roles of interleukin-6 in the central nervous system.

Authors:  D L Gruol; T E Nelson
Journal:  Mol Neurobiol       Date:  1997-12       Impact factor: 5.590

5.  Induction of IL-6 expression by mechanical stress in the trabecular meshwork.

Authors:  Paloma B Liton; Coralia Luna; Marc Bodman; Anna Hong; David L Epstein; Pedro Gonzalez
Journal:  Biochem Biophys Res Commun       Date:  2005-10-07       Impact factor: 3.575

6.  Thymoquinone increases the expression of neuroprotective proteins while decreasing the expression of pro-inflammatory cytokines and the gene expression NFκB pathway signaling targets in LPS/IFNγ -activated BV-2 microglia cells.

Authors:  Makini K Cobourne-Duval; Equar Taka; Patricia Mendonca; Karam F A Soliman
Journal:  J Neuroimmunol       Date:  2018-05-04       Impact factor: 3.478

7.  Increased intrathecal inflammatory activity in frontotemporal dementia: pathophysiological implications.

Authors:  M Sjögren; S Folkesson; K Blennow; E Tarkowski
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-08       Impact factor: 10.154

Review 8.  Cognitive dysfunction and diabetes mellitus.

Authors:  Christopher T Kodl; Elizabeth R Seaquist
Journal:  Endocr Rev       Date:  2008-04-24       Impact factor: 19.871

9.  Glia maturation factor modulates beta-amyloid-induced glial activation, inflammatory cytokine/chemokine production and neuronal damage.

Authors:  Asgar Zaheer; Smita Zaheer; Ramasamy Thangavel; Yanghong Wu; Shailendra K Sahu; Baoli Yang
Journal:  Brain Res       Date:  2008-03-10       Impact factor: 3.252

10.  New in vitro highly cytotoxic platinum and palladium cyanoximates with minimal side effects in vivo.

Authors:  Stephanie D Dannen; Lauren Cornelison; Paul Durham; John E Morley; Kiana Shahverdi; Junwei Du; Haiying Zhou; Leland C Sudlow; Daniel Hunter; Matthew D Wood; Mikhail Y Berezin; Nikolay Gerasimchuk
Journal:  J Inorg Biochem       Date:  2020-05-06       Impact factor: 4.155

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.